Quest Diagnostics Completes Sale of HemoCue Business to Radiometer Medical ApS
News Apr 10, 2013
HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide.
In February 2013, Quest Diagnostics announced it had entered into a definitive agreement to sell HemoCue to Radiometer, with plans to use the proceeds to repurchase approximately $300 million of Quest Diagnostics shares as part of the company's stock buyback program.
The transaction follows an announcement by Quest Diagnostics late last year that it would seek strategic alternatives for certain non-core business assets in order to concentrate on its diagnostic information services business. In December 2012, the company divested OralDNA Labs.
Specific Set of Nerve Cells Controls Seizures’ Spread Through BrainNews
This discovery could lead to new and better treatments for epilepsy.READ MORE
Classification Can Lead to New Ways to Diagnose CancerNews
A novel approach to studying cancer has enabled researchers to group about 10,000 human cancers of 32 different types into 10 classes based on the molecular pathways that drive tumor growth.READ MORE
New Technology Enables Identification of Biomarkers for a Wide Range of DiseasesNews
Scientists have developed a way to identify biomarkers for a wide range of diseases by assessing the antibodies we are making to the complex sugars coating our cells.READ MORE